Asmita Ahuja, MD
Hematology/Oncology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 4 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
10 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ahuja’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
California Medical Board record
Licence A144455 · Current
Licensed to practise in California · since 2016 · expires 2028-03-31 · Sardar Patel University, Pramukhswami Medical College.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$18,820
Medicare paid this office $18,820 for 117 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 34 | $5,358 | $78 |
| Short return visit (20+ min) | 48 | $3,613 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,881 | $118 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,767 | $74 |
| New patient visit (30+ min) | 11 | $591 | $54 |
Who their Medicare patients are
117 Original Medicare patients in 2024. Average age 73 · Under 65 14% · 85 and older 19% · Women 50% · Also on Medicaid 74% · Health risk score 2.27. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 41% · Cancer 32% · Chronic kidney disease 28% · Heart failure 27% · Coronary heart disease 25% · Atrial fibrillation 24% · COPD 15% · Depression 14% · Dementia 10% · Stroke 10%.
The office billed $177,281, Medicare allowed $25,879 and paid $18,820; for 240 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 117 | 240 | 73 | 2.27 | $177,281 | $18,820 |
| 2023 | 73 | 143 | 74 | 2.49 | $99,523 | $12,170 |
| 2022 | 91 | 228 | 73 | 1.43 | $122,395 | $18,376 |
| 2021 | 78 | 161 | 74 | 1.77 | $67,208 | $12,368 |
| 2020 | 77 | 155 | 69 | 1.80 | $38,461 | $5,156 |
| 2014 | 345 | 1,240 | 70 | 3.89 | $160,103 | $84,403 |
| 2013 | 185 | 655 | 70 | 3.55 | $63,393 | $45,936 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 35 | $5,781 | $84 |
| Short return visit (20+ min) | 23 | $1,332 | $55 |
2022: 5 services
| Short return visit (20+ min) | 34 | $4,805 | $86 |
| Return visit (30+ min) | 22 | $3,186 | $86 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $2,874 | $80 |
| Return visit (30+ min) | 13 | $2,106 | $124 |
| Short return visit (20+ min) | 20 | $1,540 | $53 |
2021: 3 services
| Telephone medical discussion with physician, 21-30 minutes | 53 | $8,274 | $87 |
| Telephone medical discussion with physician, 5-10 minutes | 24 | $797 | $30 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $788 | $56 |
2020: 3 services
| Telephone medical discussion with physician, 11-20 minutes | 35 | $1,923 | $39 |
| Telephone medical discussion with physician, 5-10 minutes | 59 | $1,572 | $19 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $1,386 | $66 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 243 | $47,387 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 64 | $10,896 | $160 |
| Hospital discharge day management, 30 minutes or less | 156 | $9,360 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 69 | $7,850 | $108 |
| Initial hospital observation care per day, typically 50 minutes | 26 | $2,797 | $108 |
| Hospital observation care on day of discharge | 32 | $1,838 | $57 |
| Initial hospital care with same-day admission and discharge with moderate level of medical decision making, per day at least 70 minutes | 11 | $1,476 | $134 |
| Follow-up observation care per day, typically 15 minutes | 12 | $380 | $32 |
2013: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 114 | $24,439 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $11,215 | $152 |
| Hospital discharge day management, 30 minutes or less | 59 | $3,262 | $54 |
| Initial hospital observation care per day, typically 70 minutes | 20 | $2,905 | $138 |
| Hospital observation care on day of discharge | 14 | $779 | $56 |
Medicaid work
$1,646 in 2024
Medicaid paid $1,646 for 989 billed services this clinician did in 2024, up to 51 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 192 | $851 |
| Short return visit (20+ min) | 171 | $644 |
| New patient visit (30+ min) | 57 | $151 |
| Medication list documented in medical record (COA) | 290 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 279 | $0 |
| 2024 | 989 | 5 | 51 | $1,646 |
| 2023 | 299 | 3 | 39 | $1,041 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 242 | $954 |
| Short return visit (20+ min) | 38 | $88 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 19 | $0 |
Drugs they prescribed that Part D paid
$919,897
Pharmacies billed $919,897 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
209 generic and 83 brand-name prescriptions · $919,897 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenvima | 13 | $252,618 | $19,432 |
| Xtandi | 13 | $164,566 | $12,659 |
| Promacta | 11 | $91,359 | $8,305 |
| Fluconazole | 12 | $1,492 | $124 |
| Hydroxyurea | 21 | $799 | $38 |
See all 10 drugs
| Lenvima | 13 | $252,618 | $19,432 |
| Xtandi | 13 | $164,566 | $12,659 |
| Promacta | 11 | $91,359 | $8,305 |
| Fluconazole | 12 | $1,492 | $124 |
| Hydroxyurea | 21 | $799 | $38 |
| Anastrozole | 22 | $333 | $15 |
| Acyclovir | 13 | $226 | $17 |
| Prednisone | 23 | $154 | $7 |
| Dexamethasone | 21 | $122 | $6 |
| Tamsulosin | 15 | $43 | $3 |
Year by year
| 2024 | 292 | 39 | None | 28% | $919,897 |
| 2023 | 327 | 44 | None | None | $976,845 |
| 2022 | 165 | 28 | 9% (14) | 18% | $234,927 |
| 2021 | 73 | 15 | None | 22% | $29,314 |
| 2020 | 248 | 86 | None | 18% | $266,835 |
| 2019 | 511 | 101 | 11% (57) | 15% | $376,264 |
| 2018 | 216 | 72 | 14% (30) | 22% | $293,016 |
| 2017 | 21 | 12 | None | None | $40,341 |
| 2016 | 15 | None | None | 0% | $244 |
| 2014 | 117 | 45 | 12% (14) | None | $12,255 |
| 2013 | 105 | 40 | 18% (19) | None | $3,515 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Xtandi | 14 | $182,374 | $13,027 |
| Promacta | 12 | $95,594 | $7,966 |
| Abiraterone Acetate | 15 | $37,066 | $2,471 |
| Xarelto | 12 | $6,947 | $579 |
| Aprepitant | 11 | $6,326 | $575 |
| Hydroxyurea | 24 | $1,206 | $50 |
| Anastrozole | 23 | $771 | $34 |
| Prochlorperazine Maleate | 15 | $211 | $14 |
| Dexamethasone | 22 | $191 | $9 |
| Ondansetron | 21 | $188 | $9 |
| Prednisone | 23 | $123 | $5 |
| Tamsulosin | 15 | $53 | $4 |
2022: 5 drugs
| Abiraterone Acetate | 13 | $46,977 | $3,614 |
| Anastrozole | 15 | $287 | $19 |
| Bicalutamide | 13 | $170 | $13 |
| Ondansetron | 15 | $113 | $8 |
| Prednisone | 14 | $77 | $6 |
2021: 1 drug
| Hydroxyurea | 12 | $272 | $23 |
2020: 5 drugs
| Xarelto | 14 | $7,547 | $539 |
| Hydroxyurea | 38 | $1,876 | $49 |
| Anastrozole | 49 | $1,021 | $21 |
| Letrozole | 29 | $989 | $34 |
| Ondansetron | 15 | $214 | $14 |
2019: 14 drugs
| Revlimid | 13 | $188,109 | $14,470 |
| Xarelto | 14 | $6,566 | $469 |
| Hydroxyurea | 46 | $2,155 | $47 |
| Anastrozole | 76 | $1,299 | $17 |
| Letrozole | 38 | $1,003 | $26 |
| Hydrocodone-Acetaminophen | 23 | $908 | $39 |
| Dexamethasone | 16 | $398 | $25 |
| Ondansetron | 21 | $397 | $19 |
| Warfarin | 16 | $267 | $17 |
| Gabapentin | 16 | $177 | $11 |
| Tramadol | 13 | $140 | $11 |
| Prednisone | 12 | $57 | $5 |
| Alprazolam | 13 | $48 | $4 |
| Furosemide | 14 | $15 | $1 |
2018: 4 drugs
| Hydroxyurea | 46 | $2,511 | $55 |
| Anastrozole | 12 | $180 | $15 |
| Ondansetron | 12 | $156 | $13 |
| Prednisone | 11 | $112 | $10 |
2014: 1 drug
| Lisinopril | 11 | $54 | $5 |
2013: 2 drugs
| Hydrocodone-Acetaminophen | 14 | $117 | $8 |
| Prednisone | 12 | $43 | $4 |
Money from drug and device companies
$121 in 2025
| 2025 | 1 | 1 | None | $121 |
| 2022 | 1 | 2 | None | $63 |
| 2021 | 1 | 1 | None | $13 |
| 2020 | 11 | 20 | None | $541 |
| 2019 | 16 | 92 | None | $1,885 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $121 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Lynparza | $121 |
See earlier years (2022, 2021, 2020, 2019)
2022: $63
| Amgen | Nplate | $63 | 2 payments
|
2021: $13
| Pfizer | Inlyta | $13 | 1 payment
|
2020: $541
| Janssen Biotech | Erleada | $144 | 3 payments
|
| Seagen | Adcetris | $116 | 2 payments
|
| Pfizer | Xalkori | $110 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $35 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $33 | 2 payments
|
| Kite Pharma | Yescarta | $25 | 1 payment
|
| Genentech USA | Alecensa | $23 | 1 payment
|
| Eisai | Lenvima | $20 | 1 payment
|
| Incyte | Jakafi | $12 | 1 payment
|
| Puma Biotechnology | Nerlynx | $12 | 1 payment
|
| Stemline Therapeutics | Elzonris | $11 | 1 payment
|
2019: $1,885
| Amgen | Kyprolis | $406 | 16 payments
|
| Pfizer | Ibrance | $354 | 28 payments
|
| Octapharma USA | Fibryga | $196 | 3 payments
|
| Genentech USA | Perjeta | $146 | 8 payments
|
| Celgene | Revlimid | $116 | 8 payments
|
| Sanofi-Aventis U.S. | Jevtana | $99 | 1 payment
|
| Genzyme | Jevtana | $95 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $78 | 4 payments
|
| EMD Serono | Bavencio | $66 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $65 | 3 payments
|
| Gilead Sciences | None | $58 | 3 payments
|
| Incyte | Jakafi | $58 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $49 | 3 payments
|
| Merck Sharp & Dohme | Lynparza | $40 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $39 | 1 payment
|
| Seattle Genetics | Adcetris | $21 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053543942
- Licence
- CA 144455California A144455: Current · expires 2028-03-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 532 Adeline Avenue, San Jose, CA, 95136
- NPI first listed
- 2009-08-11
- NPI last updated
- 2026-09-11
- NPI record certified
- 2026-09-11
This is when the NPI record was last certified, not a medical board exam.